Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients with Solid Tumors.

Marcel YibirinKhalis MustafayevJeff HosryPooja PundhirJoseph KlingenEduardo Yepez GuevaraBruno P GranwehrAhmed KasebAung NaingSapna PatelAmishi Y ShahFerdinandos SkoulidisHussein A TawbiLan WangEthan MillerHao Chi ZhangAmado Zurita-SaavedraHarrys A Torres

Published in: The American journal of gastroenterology (2023)

Inhibition of HCV replication with virologic cure can develop in patients receiving ICIs without DAAs. HCV reactivation occurs primarily in patients receiving immunosuppressants for ICI-related toxic effects. ICIs are safe in HCV-infected patients with solid tumors. Chronic HCV infection should not be considered a contraindication for ICI therapy.

Keyphrases

hepatitis c virus
human immunodeficiency virus
hiv infected
antiretroviral therapy
drug induced
stem cells